Related Experiment Video

Updated: Jun 10, 2026

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

Anti-tumor activity of splice-switching oligonucleotides

John A Bauman1, Shyh-Dar Li, Angela Yang

  • 1Department of Pharmacology and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA. john_bauman@med.unc.edu

Nucleic Acids Research
|August 20, 2010
PubMed

Insights

Splice-switching oligonucleotides (SSOs) targeting Bcl-x pre-mRNA reduced melanoma tumor growth in vivo. This study demonstrates the potential of SSOs delivered via lipid nanoparticles as a novel anti-cancer therapy.

Area of Science:

  • Molecular biology
  • Cancer therapy
  • RNA therapeutics

Background:

  • Alternative splicing is a key regulator of gene function and a target for molecular therapies.
  • Splice-switching oligonucleotides (SSOs) modulate splicing by binding to pre-mRNA, but their in vivo delivery to tumor cells remains a challenge.
  • The anti-apoptotic protein Bcl-x(L) is upregulated in many cancers, contributing to chemoresistance and making it a significant therapeutic target.

Purpose of the Study:

  • To evaluate the efficacy of SSOs in modulating Bcl-x alternative splicing and their anti-tumor activity against metastatic melanoma in vivo.
  • To assess the delivery of SSOs using lipid nanoparticles for targeting tumor cells.

Main Methods:

  • Splice-switching oligonucleotides (SSOs) were designed to redirect Bcl-x pre-mRNA splicing from the anti-apoptotic Bcl-x(L) isoform to the pro-apoptotic Bcl-x(S) isoform.
  • SSOs were encapsulated in lipid nanoparticles for in vivo delivery.
  • The effect of SSO treatment on Bcl-x splicing, tumor load, and metastasis was evaluated in B16F10 melanoma cell cultures and tumor xenografts.

Main Results:

  • Administration of lipid nanoparticles containing Bcl-x SSOs successfully modified Bcl-x pre-mRNA splicing in lung metastases.
  • Treatment with Bcl-x SSOs resulted in a significant reduction in tumor load compared to control groups.
  • Lipid nanoparticles alone or formulated with a control SSO showed no significant anti-tumor effect.

Conclusions:

  • SSOs targeting Bcl-x pre-mRNA demonstrate in vivo anti-tumor activity against metastatic melanoma.
  • Lipid nanoparticle delivery of SSOs is an effective strategy for targeting cancer cells and modulating alternative splicing in vivo.
  • These findings support the potential of SSO-based therapies for treating Bcl-x-driven cancers.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...